Healio Gastroenterology

01/07/2024

Healio will present its seventh annual Disruptive Innovators Awards for gastroenterology and hepatology this fall.

Healio will present its seventh annual Disruptive Innovators Awards for gastroenterology and hepatology this fall. Individuals who have changed the face of the specialty and pushed the status quo toward betterment of the field will be recognized during a prestigious awards ceremony at the ACG Annual...

01/07/2024

Reintroduction of fructans and galacto-oligosaccharides was linked to worsened abdominal pain among patients with irritable bowel syndrome who had responded to the low-FODMAP diet, according to research.

Reintroduction of fructans and galacto-oligosaccharides was linked to worsened abdominal pain among patients with irritable bowel syndrome who had responded to the low-FODMAP diet, according to research. “At present, it is assumed that the clinical benefits of the low-FODMAP diet result from r...

30/06/2024

Individuals with high genetic risk for gastric cancer may benefit from H. pylori treatment

Treatment for Helicobacter pylori infection was associated with reduced risk for gastric cancer among patients with a high genetic risk, suggesting that chemoprevention should be personalized to genetic risk, according to data. “A heritability of 22% has been previously estimated for gastric c...

30/06/2024

FDA clears first ‘rapid diagnostic’ hepatitis C RNA test for point-of-care settings

The FDA granted marketing authorization for Cepheid’s Xpert HCV test and GeneXpert Xpress System, the first rapid test for hepatitis C virus intended for use in point-of-care settings. According to the agency, the test detects HCV RNA using a fingertip blood sample, allowing results to be deli...

29/06/2024

New approach uses real-world data to identify the most potentially hepatotoxic medications

Researchers have developed a data-driven, systematic approach for classification of the most potentially hepatotoxic medications based on incidence rates of severe acute liver injury, rather than published case report counts. “From a clinical standpoint, knowing the rate of severe ALI after st...

28/06/2024

Treatment for Helicobacter pylori infection was associated with reduced risk for gastric cancer among patients with a high genetic risk, suggesting that chemoprevention should be personalized to genetic risk, according to data.

Treatment for Helicobacter pylori infection was associated with reduced risk for gastric cancer among patients with a high genetic risk, suggesting that chemoprevention should be personalized to genetic risk, according to data. “A heritability of 22% has been previously estimated for gastric c...

28/06/2024

The FDA granted marketing authorization for Cepheid’s Xpert HCV test and GeneXpert Xpress System, the first rapid test for hepatitis C virus intended for use in point-of-care settings.

The FDA granted marketing authorization for Cepheid’s Xpert HCV test and GeneXpert Xpress System, the first rapid test for hepatitis C virus intended for use in point-of-care settings. According to the agency, the test detects HCV RNA using a fingertip blood sample, allowing results to be deli...

28/06/2024

Ongoing campaign calls on UHC to rethink looming program on GI procedures

As part of its ongoing campaign against UnitedHealthcare and the insurer’s plans to implement the Gold Card program for gastrointestinal endoscopy procedures, AGA encourages all supporters to use the hashtag on social media.“We need to keep the pressure on UHC by sharing how bad...

27/06/2024

IBS symptom reduction ‘twice as large’ with dietary intervention vs. medical treatment

Although two restrictive diets and medical treatment all reduced the severity of symptoms in irritable bowel syndrome, the effect was greater with diets, suggesting their potential as first-line treatment, according to researchers. “As IBS is a disorder that can manifest in different ways amon...

27/06/2024

Researchers have developed a data-driven, systematic approach for classification of the most potentially hepatotoxic medications based on incidence rates of severe acute liver injury, rather than published case report counts.

Researchers have developed a data-driven, systematic approach for classification of the most potentially hepatotoxic medications based on incidence rates of severe acute liver injury, rather than published case report counts. “From a clinical standpoint, knowing the rate of severe ALI after st...

26/06/2024

As part of its ongoing campaign against UnitedHealthcare and the insurer’s plans to implement the Gold Card program for gastrointestinal endoscopy procedures, AGA encourages all supporters to use the hashtag on social media.

As part of its ongoing campaign against UnitedHealthcare and the insurer’s plans to implement the Gold Card program for gastrointestinal endoscopy procedures, AGA encourages all supporters to use the hashtag on social media.“We need to keep the pressure on UHC by sharing how bad...

26/06/2024

Higher adalimumab concentration linked to complete healing in perianal fistulizing Crohn’s

An adalimumab concentration threshold of 12.1 µg/mL “may be a target for therapeutic drug monitoring” to achieve complete fistula healing in perianal fistulizing Crohn’s disease, according to research in Clinical Gastroenterology and Hepatology. “Patients with perianal....

25/06/2024

Although two restrictive diets and medical treatment all reduced the severity of symptoms in irritable bowel syndrome, the effect was greater with diets, suggesting their potential as first-line treatment, according to researchers.

Although two restrictive diets and medical treatment all reduced the severity of symptoms in irritable bowel syndrome, the effect was greater with diets, suggesting their potential as first-line treatment, according to researchers. “As IBS is a disorder that can manifest in different ways amon...

24/06/2024

An adalimumab concentration threshold of 12.1 µg/mL “may be a target for therapeutic drug monitoring” to achieve complete fistula healing in perianal fistulizing Crohn’s disease, according to research in Clinical Gastroenterology and Hepatology.

An adalimumab concentration threshold of 12.1 µg/mL “may be a target for therapeutic drug monitoring” to achieve complete fistula healing in perianal fistulizing Crohn’s disease, according to research in Clinical Gastroenterology and Hepatology. “Patients with perianal...

23/06/2024

Nearly 62% achieve MASH resolution without worsening of fibrosis with tirzepatide

Patients with metabolic dysfunction-associated steatohepatitis and advanced fibrosis treated with tirzepatide achieved significant disease resolution without worsening of fibrosis, compared with those on placebo, according to research. “Tirzepatide, a once-weekly glucose-dependent insulinotrop...

21/06/2024

VIDEO: Larsucosterol reduces mortality by more than 50% in alcohol-associated hepatitis

In a Healio video exclusive, Mitchell L. Shiffman, MD, reports that U.S. patients with severe alcohol-associated hepatitis treated with larsucosterol experienced a “statistically significant” reduction in 90-day mortality — more than 50%. “Severe alcohol use and alcoholic hep...

21/06/2024

Patients with metabolic dysfunction-associated steatohepatitis and advanced fibrosis treated with tirzepatide achieved significant disease resolution without worsening of fibrosis, compared with those on placebo, according to research.

Patients with metabolic dysfunction-associated steatohepatitis and advanced fibrosis treated with tirzepatide achieved significant disease resolution without worsening of fibrosis, compared with those on placebo, according to research. “Tirzepatide, a once-weekly glucose-dependent insulinotrop...

20/06/2024

Oral androgen receptor agonist improves sarcopenia over 52 weeks in men with cirrhosis

LPCN 1148, an oral androgen receptor agonist, improved sarcopenia in men with advanced cirrhosis as early as week 12 — with sustained improvement through 52 weeks — and reduced recurrence of encephalopathy, according to late-breaking data. “Sarcopenia is common in cirrhosis and imp...

20/06/2024

Research highlights ‘serious unmet need’ for LT in severe acute-on-chronic liver failure

Interim results from a global, multicenter study demonstrated the benefit of liver transplantation among patients with acute-on-chronic liver failure grades 2 and 3 and suggest that current allocation systems are inadequate. In the observational CHANCE study, Rajiv Jalan, MD, PhD, of the University....

19/06/2024

In a Healio video exclusive, Mitchell L. Shiffman, MD, reports that U.S. patients with severe alcohol-associated hepatitis treated with larsucosterol experienced a “statistically significant” reduction in 90-day mortality — more than 50%.

In a Healio video exclusive, Mitchell L. Shiffman, MD, reports that U.S. patients with severe alcohol-associated hepatitis treated with larsucosterol experienced a “statistically significant” reduction in 90-day mortality — more than 50%. “Severe alcohol use and alcoholic hep...

19/06/2024

LPCN 1148, an oral androgen receptor agonist, improved sarcopenia in men with advanced cirrhosis as early as week 12 — with sustained improvement through 52 weeks — and reduced recurrence of encephalopathy, according to late-breaking data.

LPCN 1148, an oral androgen receptor agonist, improved sarcopenia in men with advanced cirrhosis as early as week 12 — with sustained improvement through 52 weeks — and reduced recurrence of encephalopathy, according to late-breaking data. “Sarcopenia is common in cirrhosis and imp...

19/06/2024

Today is a day for reflection, celebration, and strength. We wish you all a festive and meaningful .

18/06/2024

Interim results from a global, multicenter study demonstrated the benefit of liver transplantation among patients with acute-on-chronic liver failure grades 2 and 3 and suggest that current allocation systems are inadequate.

Interim results from a global, multicenter study demonstrated the benefit of liver transplantation among patients with acute-on-chronic liver failure grades 2 and 3 and suggest that current allocation systems are inadequate. In the observational CHANCE study, Rajiv Jalan, MD, PhD, of the University....

16/06/2024

VIDEO: Lifetime disruptor ‘just getting started’ in quest to elevate care for IBD patients

Marla C. Dubinsky, MD, winner of the 2023 Healio Lifetime Disruptor Award, was first inspired to “disrupt the space” after witnessing patients with inflammatory bowel disease become frustrated with lack of support and access to care. “Because the price of medications are quite cost...

15/06/2024

AGA recommends endoscopic eradication vs. surveillance for BE with high-grade dysplasia

In a new clinical practice guideline, the AGA provides evidence-based recommendations for use of endoscopic eradication therapy in the management of Barrett’s esophagus, accounting for the presence of dysplasia and other scenarios. “The advent of endoscopic eradication therapy (EET) for...

14/06/2024

Bulevirtide monotherapy ‘may prevent decompensation but not HCC’ in HDV, cirrhosis

Over 2 years, bulevirtide monotherapy reduced the risk for decompensation and mortality, but not hepatocellular carcinoma, among patients with hepatitis D virus and compensated cirrhosis compared with untreated patients. “Bulevirtide, the first-in-class entry inhibitor, has been approved by EM...

14/06/2024

Marla C. Dubinsky, MD, winner of the 2023 Healio Lifetime Disruptor Award, was first inspired to “disrupt the space” after witnessing patients with inflammatory bowel disease become frustrated with lack of support and access to care.

Marla C. Dubinsky, MD, winner of the 2023 Healio Lifetime Disruptor Award, was first inspired to “disrupt the space” after witnessing patients with inflammatory bowel disease become frustrated with lack of support and access to care. “Because the price of medications are quite cost...

14/06/2024

MASH patients with high BMI, weight respond ‘slightly better’ to higher Rezdiffra dose

Patients with metabolic dysfunction-associated steatohepatitis who weigh more than 100 kg or a BMI more than 35 kg/m² had “slightly better” response with a 100 mg dose of Rezdiffra, according to data presented at EASL Congress.“MAESTRO-NASH was the pivotal phase 3 study supporting...

13/06/2024

FDA approves Ipsen’s Iqirvo ‘to address unmet need’ in primary biliary cholangitis

The FDA granted accelerated approval to Ipsen Pharma’s Iqirvo 80 mg, a first-in-class oral, once-daily peroxisome proliferator-activated receptor agonist for the treatment of primary biliary cholangitis, according to a company release. Originally given breakthrough therapy designation in 2019,...

13/06/2024

In a new clinical practice guideline, the AGA provides evidence-based recommendations for use of endoscopic eradication therapy in the management of Barrett’s esophagus, accounting for the presence of dysplasia and other scenarios.

In a new clinical practice guideline, the AGA provides evidence-based recommendations for use of endoscopic eradication therapy in the management of Barrett’s esophagus, accounting for the presence of dysplasia and other scenarios. “The advent of endoscopic eradication therapy (EET) for...